Last reviewed · How we verify
NCT05007886
Remote Evaluation of the Naída CI M90 (Marvel) Sound Processor
trial in Cochlear Hearing Loss in 20 participants. Status unknown.
1 September 2022
Quick facts
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 13 August 2021 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Cochlear Hearing Loss — all drugs for Cochlear Hearing Loss →
- Hearing Loss — all drugs for Hearing Loss →
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Who can join
18 and older, any sex, with Cochlear Hearing Loss or Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Within-subject comparison. Remotely Evaluating latest Advanced Bionics Marvel Sound Processor for cochlear implants, from two adult groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05007886
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cochlear Hearing Loss
Currently open trials in the same condition.
- NCT07509788 — Effects of Binaural Hearing on Listening Effort and Cognitive Development in Mandarin-speaking Children With Cochlear Im · recruiting
- NCT07068373 — Development of Evidence-based Therapeutic Guidelines for Early SLA in Urdu-speaking Children With Cochlear Implants · active not recruiting
- NCT06960616 — Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy · NA · recruiting
- NCT05486637 — Vocal Emotion Communication With Cochlear Implants · EARLY_PHASE1 · recruiting
Other Cambridge University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
- NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
- NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
- NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05007886 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
- Last refreshed: 19 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05007886.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing